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Radiomics is a converging multidisciplinary field of
translational medicine aimed at automatic and completely
data-centric diagnosis of any disease entity in individual
patients using a variety of medical imaging technology
and machine learning (ML) methodology. This usually
entails the use of automated techniques for data processing
and analysis followed by the application of powerful
statistical solutions for predicting accurate diagnosis
and prognosis on a single-subject basis. A wide array
of computing methods have been developed for data
reduction, feature extraction and classification. As a
surrogate marker of synaptic activity, regional cerebral
glucose metabolism measured with 18F-fluorodeoxyglucose
(FDG) positron emission tomography (PET) has been
one of most versatile and cost-effective neuroimaging
biomarkers in the field of neurodegenerative disorders.
Indeed, this biomarker has been widely used in the
objective assessment of early differential diagnosis, clinical
correlation, disease progression and therapeutic response
in patients with Parkinson’s disease (PD) as well as with
atypical parkinsonism (APD) including multiple system
atrophy (MSA), progressive supranuclear palsy (PSP) and
corticobasal degeneration (CBD) (1-5). Both regional and
brain network biomarkers are used in clinical and research
applications of translational medicine based on mean and
variance information of glucose metabolism provided by
FDG PET. It is still a challenge to distinguish PD from any
form of APD at early clinical stages despite the tremendous
achievements over the last decade.
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Discrimination of PD from healthy controls
A recent article on this journal reported a new method to
discriminate early-stage patients with PD from normal
control (NC) subjects using radiomic features extracted
from brain FDG PET images (6). The work involved
supervised feature selection based on texture analysis in a set
of predetermined anatomical regions of interest alongside
a classifier built with a support vector machine (SVM). The
study taps into valuable diagnostic information from highdimensional radiomic features that reflect regional brain
tissue heterogeneity revealed by FDG PET. The diagnostic
performance of this method was evaluated rigorously with
bootstrap resampling where a large cohort of PD and NC
subjects at one center were used as training and test sets
with five-fold cross-validation, while a small cohort of PD
and NC subjects at another center were used as a separate
test set. Main outcomes were the accuracy, sensitivity and
specificity averaged across multiple runs for each of the two
test datasets. The authors showed high diagnostic accuracy
in comparable patients with PD at early clinical stages
versus age- and gender-matched healthy controls from two
medical centers.
This study has put forth several major advances in the
development of computer aided diagnosis for PD and
related disorders with FDG PET. The authors selected
26 subcortical and cortical anatomical volumes of interest
(VOIs) known to have abnormal metabolism from prior
published studies. The matrix-based analysis resulted in
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43 texture features, 188 wavelet features and 4 intensity
features for each VOI. They then identified 30 independent
radiomic features most relevant for disease discrimination
by using autocorrelation and Fisher scoring algorithms. Of
interest, the 10 top-ranked features were found across a set
of relatively hypermetabolic regions of pons, cerebellum,
pallidum and supplementary motor area (MSA) and
relatively hypometabolic regions of inferior occipital cortex.
In this study, three kernel (linear, sigmoid, and radial basis)
functions were included to assess the ability of feature
generalization and the reliability of SVM classification (6).
The authors showed that diagnosis by the SVM classifier
was similar among the three different kernels and improved
slightly versus another classifier based on random forest.
They further demonstrated with both classifiers that
radiomic features provided superior classification compared
to the traditional method that used features from mean
metabolic values in these VOIs, and the combination of
both types of features increased the diagnostic accuracy
moderately. The latter is expected because some of these
features were weakly correlated as predictive variables.
One important finding of this study is that some highfrequency radiomic features in the right pons, SMA
and cerebellum correlated positively with clinical stages
or severity of motor symptoms and also variably with
corresponding metabolic values in these regions in the
combined cohort of patients with PD. Thus, the top
discriminatory radiomic features selected by the algorithms
captured disease-related signatures despite their weak but
significant associations with clinical variables and abnormal
regional metabolism. This is also not surprising given the
prior hypothesis concerning the VOIs included in the study
as well as the strategy underling the extraction and selection
of diagnostic features.
There are several areas of interest worth of further
investigations on this topic. Firstly, decision scores
produced for individual subjects by the SVM classifier
appear to be a promising biomarker but this potential has
to be fully evaluated with the same dataset for diagnostic
use and clinical correlation. Secondly, it may be worthwhile
to incorporate clinical stage and disease severity of patients
in the ML models to improve the replicability across sites,
in addition to the demographic information of individual
subjects. Thirdly, it would be of importance to examine
whether regionally-specific radiomic features have anything
to do with clinical asymmetry of motor symptoms and
subtype (i.e., akinesia, rigidity and resting tremor) rating
scales in PD. Fourthly, the questions remain about whether
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diagnostic performance can be further enhanced by using
ratio images compared to those of standard uptake value
(SUV) considering that the sensitivity for detecting group
difference in regional glucose metabolism is often increased
with FDG PET image ratio-normalized by mean value
in a reference region like gray matter or white matter.
Finally, although the proposed ML techniques marginally
outperformed the diagnostic accuracy of deep belief
learning network, it may be more valuable to compare
with other innovative methods like deep convoluted neural
network demonstrating superior accuracy for early diagnosis
of PD versus NC subjects using a more specific biomarker
of dopaminergic dysfunction (7).
One technical limitation of this study is that the large
anatomical VOIs selected from the standard brain atlas are
still primarily hypothesis-driven and may be less sensitive
to localized metabolic alteration in PD. This was so despite
the partial confirmation of these VOIs by the authors in
comparison with brain mapping analysis in the large cohort
of patients with PD and healthy controls (6). It would be
necessary to determine whether diagnosis can be improved
using radiomic features derived from more specific regions
of abnormal glucose metabolism defined by voxel-wise brain
mapping analysis with either univariate and multivariate
models in neurodegenerative disorders (8,9). These can
also offer disease-specific brain masks to help implement
or refine any completely voxel-based ML algorithms for
differential diagnosis.
Since early 2000s many studies with FDG PET images
and voxel-based principal component analysis (PCA) have
shown that individual patients with PD can be assessed
reliably by elevated expression scores of a specific diseaserelated metabolic pattern called PDRP, which is highly
reproducible across multiple imaging centers worldwide
(5,10,11). It is worth noting that subject sores of PDRP
demonstrated much stronger clinical correlations in early
stage PD (11,12) than those with radiomic features as
reported in the study by the authors (6). To this end it
would be straight-forward to compare the performance
of discriminating PD patients from healthy controls by
using features obtained from subject scores of PDRP in
the Chinese population (13) and determine whether this
network biomarker could be incorporated in the predictive
models to further increase the diagnostic accuracy.
Another topic of growing interest was to examine whether
the diagnostic methods proposed by the authors could
help predict the onset of PD in prodromal patients with
rapid eye movement sleep behavior disorder as reported
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previously by subject scores of PDRP (14,15).
Early differential diagnosis
In clinical practice it is less a challenge to distinguish
patients with PD from NC subjects by itself than from
patients with APD. Typically, patients with uncertain
diagnosis of parkinsonian disorders at early-stage consist
of approximately 80% with PD and 20% with APD;
some of whom may have never been treated with any
antiparkinsonian medications. This study revealed relatively
high performance in diagnosis given variable clinical stage
and disease severity in patient cohorts across both centers (6).
Nevertheless, the finding was limited by the absence of
APD subjects and the retrospective nature of the study.
The authors could test the specificity of their diagnostic
methods by simply including APD subject as an additional
test cohort.
Down the road the present studies could be extended to
extract other disease-specific radiomic features associated
with MSA, PSP and CBD. Diagnosis for each clinical
phenotype of parkinsonism can be realized by a binary
classification of PD versus APD and a multi-category
classification among APD themselves. The primary premise
of this approach is that diagnostic accuracy for PD would
be higher by merely identifying and excluding APD.
The performance of such a diagnosis at baseline must be
confirmed prospectively until a final diagnosis is made after
several years of clinical follow-up. Indeed, one study with
FDG PET reported previously that the accuracy was high
in discriminating PD from APD but poor for diagnosing
each phenotype of APD with voxel-based features derived
using relevance vector machine (16). By contrast, this
strategy has produced superior differential diagnosis in
terms of excellent specificity and positive predictive value
even at early stage, by using multi-disease metabolic
patterns as diagnostic features along with novel classification
methods based on multivariate regression (1). The key input
is subject scores computed in a large cohort of clinically
undiagnosed parkinsonian subjects for metabolic brain
networks associated specifically with PD, MSA and PSP.
These disease-related brain networks had been identified
previously in clinically established American patients by
pattern recognition with supervised PCA based on brainwide volumetric variance information of regional glucose
metabolism (17,18). Subsequently, this robust method for
differential diagnosis was cross-validated prospectively in
a completely independent cohort in India (19), and proved
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highly valuable in helping select PD patients for a successful
multi-center clinical trial of gene therapy (20). It would be
important to compare these methods with other related ML
algorithms based on radiomic signatures extracted from
independent component analysis (21) as well as partial least
squares (22).
One major limitation commonly seen in the design
of supervised ML algorithms is that training is mostly
performed using homogeneous dataset at one site followed
by testing using mixed dataset across multiple sites. More
rigorous cross-validation in truly independent medical
centers is warranted in light of differences in PET camera
systems, imaging protocols, attenuation correction methods,
image reconstruction algorithms, and any pre- or postprocessing procedures (23,24). This will provide unique
opportunity to refine ML models of learning and testing
that can fully account for these technical factors as well
as inevitable variability in patient populations and clinical
expertise in multi-center settings. It would be necessary to
evaluate whether prognostic outcomes can be improved by
including baseline independent clinical variables such as
disease profiles, medication status and chronic exposure.
Roadblock to clinical implementation
The work described in this article represents the important
first step prior to implementing more comprehensive
and rigorous radiomic approaches of this kind that can
leverage novel methods for feature extraction and adaptive
ML algorithms in the fields of artificial intelligence and
biostatistics decision-making. It would be more challenging
to extend the innovative methods put forward in this
study in the context of early and differential diagnosis
of parkinsonism. For instance, some of the top radiomic
features selected by the authors may be highly variable and
not replicable in prospective and independent validation
across multiple centers (24). Any new techniques developed
with this approach in the future should be compared with
the established methods that have already shown great
promise for early differential diagnosis of PD in more
rigorous studies.
There is still a long way to go before radiomic approaches
can find widespread applications in clinical practice. This is
mainly due to major deficiencies in the experimental design
and pitfalls in the assessment methodology that limit the
reliability and reproducibility of most ML methods (23,24).
There is also a lack of consensus among imaging specialists
and clinicians regarding different radiomic features and a
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wide array of classification algorithms. This issue may be
resolved by directly comparing different methods and using
the same outcome measures in large samples of parkinsonian
patients whose clinical diagnoses are uncertain initially but
confirmed subsequently. To ensure the total impartiality of
the outcomes in such endeavors it is essential to maintain a
double-blind study between imaging analysts and clinicians.
It is important to bear in mind that the maximum accuracy
that can be achieved by any means of diagnosis will be
limited given the heterogeneity of PD or each major form
of APD due to clinical subtypes, genetic variants and other
coexisting conditions (25). More concerted efforts are
necessary on standardization, optimization and approval of
easily accessible ML diagnostic tools in conjunction with
aligned professional societies, government regulators and
commercial vendors. This process can be accelerated by
sharing databases and analytical tools in public domain, with
the ultimate goal of achieving excellent generalizability of
the techniques and a high degree of agreement among stake
holders.
Going forwards there is an urgent need to develop
standardized radiomics methodology and diagnostic
criteria based on prospective national and international
clinical trials in real world patients suspected to have
any form of parkinsonian disorders, with longitudinal
evaluation of eventual clinical outcomes and preferably
with pathologic confirmation (1). It would be of greater
value to improve diagnostic accuracy by combining
unique features corresponding to region- or networkbased imaging biomarkers with FDG PET. There is also
general consensus that accuracy for early and differential
diagnosis can be further enhanced by including any
additional demographic and clinical information
available. Ultimately, such collective endeavors in
the field will establish the true accuracy and error
bounds of differential diagnosis in light of inherent
and sometimes large variability in both biomarkers
and clinical examination. The continued improvement
in the performance of advanced ML diagnostic tools
would promote the delivery of personalized medicine
in parkinsonism and optimize the subject selection in
clinical trials of targeted therapies.
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